CD10–MUM1+Follicular Lymphoma: A Case Report and Review of the Literature

作者: 刘一雄 * , 郭英 :西京医院病理科;

关键词: 滤泡性淋巴瘤免疫表型CD10MUM1亚型Follicular Lymphoma Immnophenotype CD10 MUM1 Subtype

目的:我院会诊一例外院无明确诊断、外周淋巴结肿大的老年患者,为明确诊断特做形态学、免疫组化及分子遗传学检测。方法:常规对福尔马林固定、石蜡包埋的淋巴结组织切片,做HE、免疫组化染色及荧光原位杂交实验。结果:免疫组化结果:瘤细胞CD20(+)、PAX-5(+)、BCL-2(+)、Mum1(+)、Bcl-6弱(+)、CD10(–)、CD23(+)、CD21(+)、CD43(–)、CyclinD1(–),Ki67增殖指数约50%。原位荧光杂交结果:IgH/BCL2易位(+),BCL6易位(–)。结论:本文介绍的滤泡性淋巴瘤病例符合较为少见的MUM1(+) CD10(–)滤泡性淋巴瘤亚型(80%)伴有弥漫性大B细胞淋巴瘤区域(20%),分级为3级b,据报道其预后较差,应当视作侵袭性淋巴瘤治疗。
Objective: In order to make definate diagnosis to an old patient with multiple lymph-node enlargement in the area of groin and submaxilla we made morphology and molecularbiology study. Methods: We carried out slice cut-ting from formalin fixed paraffin embedded tissue, then make HE and immunostaining. After that Fluorescence in situ hybridization (FISH) was performed to detect genetic abnormalities. Results: Immunostaining: CD20(+), PAX-5(+), BCL-2(+), Mum1(+), Bcl-6 weak(+), CD10(–), CD23(+), CD21(+), CD43(–), CyclinD1(–), Ki67 index was about 50%. FISH: IgH/BCL2 translocation (+), BCL6 translocation (–). Conclusion: The case we are intruducing here belongs to the rare subtype of follicular lymphoma which chracterized by MUM1(+) CD10(–) immunostaining marker. The pa-thology diagnosis is follicular lymphoma (MUM1(+) CD10(–)) (80%) with diffuse area(20%), degree: 3b. The progno-sis of this kind of follicular lymphoma is not good and should be treated as aggressive B cell lymphoma.

文章引用: 刘一雄 , 郭英 (2012) CD10–MUM1+滤泡性淋巴瘤一例及文献学习。 医学诊断, 2, 17-21. doi: 10.12677/MD.2012.23004


[1] A. K. Ganti, D. D. Weisenburger, L. M. Smith, et al. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska lymphoma study group experience. Annals of Oncology, 2006, 17(6): 920-927.

[2] K. Karube, Y. Guo, J. Suzumiya, et al. CD10–MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features and clinical features. Blood, 2007, 109(7): 3076-3079.

[3] Y. Guo, K. Karube, R. Kawano, et al. Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. Leukemia, 2005, 19(6): 1058-1063.

[4] K. Gu, W. C. Chan and R. C. Hawley. Practical detection of t(14;18) (IgH/BCL2) in follicular lymphoma. Archives of Pathology & Laboratory Medicine, 2008, 132(8): 1355-1361.

[5] N. L. Harris, S. H. Swerdlow, E. S. Jaffe, et al. Follicular lymphoma. In: S. H. Swerdlow, E. Campo, N. L. Harris, et al., Eds., Who Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008: 220-226.

[6] 郭英, 黄高升. 滤泡性淋巴瘤分型、免疫表型和遗传学变异的研究进展[J]. 国际输血及血液学杂志, 2006, 29(5): 423-425.

[7] K. N. Naresh. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1- positive high-grade subtypes. Haematologica, 2007, 92(2): 267- 268.

[8] A. Rueda, M. Casanova, M. Redondo, et al. Has the time come to leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients? BMC Cancer, 2012, 12(1): 210.

[9] A. Freedman. Follicular lymphoma: 2011 update on diagnosis and management. American Journal of Hematology, 2011, 86(9): 768-775.

[10] H. Horn, C. Schmelter, E. Leich, et al. Results: Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica, 2011, 96(9): 1327-1334.

[11] N. L. Harris, P. Kluin. Follicular lymphoma grade 3B: Is it a real disease? Haematologica, 2011, 96(9): 1244-1246.